Search clinical trials for: Myeloproliferative disorders

Total 145671 results

Dana-Farber Cancer Institute

Active, not recruiting

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasms

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Natural Killer Cells and Bortezomib to Treat Cancer

Multiple Myeloma | Chronic Myeloid Leukemia (CML) | Pancreatic Ca | Colon/Rectal Ca | Carcinoma, Non-Small -Cell Lung

United States
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Thailand, Malaysia, Korea, Republic of, Italy, United Kingdom, Poland, Germany, Turkey
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

HIV Infection | Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelogenous Leukemia, BCR-ABL1... and other conditions

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditions

United States
Diane George

Active, not recruiting

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Juvenile Myelomonocytic Leukemia (JMML) | Lymphoma (Hodgkin's and Non-Hodgkin's)

United States
Karyopharm Therapeutics Inc

Active, not recruiting

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Myelofibrosis

Spain, China, Poland, United States, France, Greece, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic... and other conditions

United States
Roswell Park Cancer Institute

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Myeloproliferative Neoplasm | Minimal Residual Disease | Graft Versus Host Disease | Severe Aplastic Anemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia... and other conditions

United States
Ottawa Hospital Research Institute
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR)... and other collaborators

Completed

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (AIRPORT-MPN)

Primary Myelofibrosis | Venous Thromboembolism (VTE) | Polycythemia Vera (PV) | Essential Thrombocythemia (ET) | JAK2 Mutation | Myeloproliferative Neoplasm (MPN)

Canada
Orca Biosystems, Inc.

Active, not recruiting

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Lymphoid Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22)... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
Kyowa Kirin, Inc.

Terminated

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Novartis Pharmaceuticals

Available

Managed Access Programs for ABL001, Asciminib

Chronic Myeloid Leukemia in Chronic Phase
Pfizer

Terminated

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Solid Tumor | Hematologic Malignancies

United States, Canada
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Minimal Residual Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

United States
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Blasts More Than 20 Percent of Bone Marrow Nucleated Cells | Blasts More Than 20 Percent of Peripheral Blood White Cells

United States
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
Incyte Corporation

Completed

INCB018424 in Patients With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Chronic Myelogenous Leukemia

United States
St. Petersburg State Pavlov Medical University

Completed

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (FluBuBe)

Myelodysplastic Syndromes | Lymphoblastic Lymphoma | Myeloproliferative Neoplasm | Leukemia, Acute Lymphoblastic | Myeloid Leukemia, Acute | Biphenotypic Acute Leukemia

Russian Federation
Novartis Pharmaceuticals

Active, not recruiting

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Chronic Myelogenous Leukemia

Spain, United Kingdom, Germany, Canada, Austria, France, Korea, Republic of, Greece, Singapore, Italy, Argentina, Poland, Vietnam, Malaysia, Oman, Brazil
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic Diseases | Chronic Myelogenous Leukemia | CML | Leukemia, Myeloid Chronic

Taiwan, Italy, Spain, United Kingdom, Germany, United States, Korea, Republic of, France, Russian Federation, Canada, Denmark, Poland, Portugal, Austria, Czechia
Novartis Pharmaceuticals

Completed

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera (PAVE)

Polycythemia Vera

Germany
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
University College, London
Bloodwise

Completed

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (UK-Haplo)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia | Chronic Lymphocytic Leukaemia | Acute Lymphoblastic Leukaemia | Chronic Myeloid Leukaemia | Acquired Bone Marrow Failure Syndromes | Other Haematological Malignancies; Unrelated HSCT Indicated

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myeloproliferative Neoplasm | Relapsed Follicular Lymphoma | Relapsed T-Cell Lymphoma and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Incyte Corporation

Terminated

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States
Pfizer

Completed

Safety And Efficacy Of Bosutinib (BLF)

Chronic Myelogenous Leukemia

Japan
National Cancer Institute (NCI)

Active, not recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative... and other conditions

United States
Indiana University

Withdrawn

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia, Adult | Bone Marrow Transplant Complications

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Myelofibrosis

China
The First Affiliated Hospital of Soochow University

Completed

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Philadelphia Chromosome | Mixed Phenotype Acute Leukemia

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Chronic Myelogenous Leukemia

United States, United Kingdom, Hungary, Japan, Saudi Arabia, Australia, Germany, Canada, France, Netherlands, Spain, Lebanon, Turkey, Korea, Republic of, Argentina, Brazil, Bulgaria, Czechia, Israel, Italy, Mexico, Romania, Russian... and more
Joseph Jurcic
Bristol-Myers Squibb

Terminated

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Myeloproliferative Neoplasm

United States
Federico II University

Completed

Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm | Prefibrotic/Early Primary Myelofibrosis

Italy
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Suspended

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Acute Myeloid Leukemia | Hodgkin Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Relapsed T-Cell Lymphoma | Relapsed Large Cell Lymphoma | Biphenotypic/Undifferentiated Leukemia

United States

Search clinical trials for: Myeloproliferative disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations